Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.

Amydis has received $2.5 million to continue mapping toxic deposits of TDP-43 in retinal tissue and develop an eye test for ...

Experimental therapy RT1999 will soon be tested in the UK EXPERTS-ALS platform trial designed to rapidly screen potential ALS treatments.

As a researcher, I still remember the discomfort I felt every time I had to sacrifice laboratory animals for an experiment.

Frontotemporal dementia (FTD), in particular, may be at play, and identifying ways to slow down its progression can help. In ...

"Watching my mom die of ALS was one of the most awful things I’ve gone through. I don’t want my children to see me suffer ...

A retinal image could help doctors quickly distinguish between similar neurodegenerative diseases, such as ALS and Alzheimer's disease, and with remarkable accuracy, according to new research ...

Loss of communication can be among the most devastating symptoms for patients with paralysis. A new study by investigators ...

Neuracle Medical Technology’s invasive brain-computer interface has been given the green light in China for people with ...

Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026Obtained alignment with FDA and ...

Amydis receives phase 2 NIH grant award of $2.5 million to advance a novel approach to detect biomarker TDP-43: San Diego Friday, March 13, 2026, 18:00 Hrs [IST] Amydis Inc., a pr ...

Researchers develop a 96% accurate AI-powered retinal scan to distinguish between Alzheimer’s and ALS by detecting specific ...